SCYNEXIS Stock

SCYNEXIS EPS Growth

The EPS Growth of SCYNEXIS (SCYX) as of Aug 9, 2026 is -131.67 %. In the previous year, EPS Growth was 194.24 % — a change of -167.79% (lower).

EPS Growth

-131.67 %

YoY

-167.79%

Last updated:

EPS Growth of SCYNEXIS is 2026 -131.67 % . EPS Growth of SCYNEXIS was 2025 194.24 % . It decreases by -167.79% lower compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

EPS Growth of SCYNEXIS is -131.67 % in 2026.

On Eulerpool you can find the complete historical development of EPS Growth SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's SCYNEXIS historically and in real time.

Access this data via the Eulerpool API

Growth — SCYNEXIS

All Key Metrics — SCYNEXIS